瑞舒伐他汀联合依折麦布调脂治疗糖尿病50例临床评价  

Clinical Evaluation on Lipid- Regulating Therapy of Rosuvastatin Combined with Ezetimibe for Treating Diabetes in 50 Cases

作　　者：李婷[1] 何剑琴[1] 陈连剑[1] 冯风明 曾妍[1] 

机构地区：[1]广东省深圳市福田区人民医院药剂科,广东深圳518033

出　　处：《中国药业》2015年第18期33-35,共3页China Pharmaceuticals

摘　　要：目的观察瑞舒伐他汀联合依折麦布治疗2型糖尿病合并高胆固醇的临床疗效及安全性。方法选择2型糖尿病合并高胆固醇患者100例,随机分成治疗组和对照组,各50例。治疗组患者在基础治疗后给予瑞舒伐他汀10 mg/d,依折麦布10 mg/d;对照组患者在基础治疗上仅给予瑞舒伐他汀10 mg/d。治疗8周后观察两组患者的空腹血糖(FPG)、餐后2 h血糖(2 h PG)、总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)、丙氨酸氨基转移酶(ALT)、血清肌酸激酶(CK)等的变化。结果治疗后,两组患者的TC及LDL-C均较治疗前显著下降(P<0.05),且治疗组下降更明显(P<0.01);治疗组HDL-C及ALT与CK均较对照组有所升高(P<0.05);治疗组FPG及2 h PG较对照组有明显改善(P<0.05)。结论瑞舒伐他汀联合依折麦布更能有效改善2型糖尿病患者血脂水平,减少不良反应,值得临床推广。Objective To investigate the clinical effect and safety of rosuvastatin combined with ezetimibe in treatment of type 2 dia-betes mellitus（T2DM）complicating hypercholesteremia. Methods 100 cases of T2DM complicating hypercholesteremia were selected and randomly divided into the treatment group and the control group,50 cases in each group. The treatment group was given rosuvastatin 10 mg/d and ezetimibe 10 mg/d after daily basic treatment,while the control group was given only rosuvastatin 10 mg/d after daily basic treatment. The changes of fasting plasma glucose（FPG）,postprandial 2 h blood glucose（2 h PG）,total cholesterol（TC）,low density lipoprotein cholesterol（LDL-C）,high density lipoprotein cholesterol（HDL-C）,alanine aminotransferase（ALT）,serum creatine kinase（CK） after 8-week treatment were observed in the two groups. Results TC and LDL-C after treatment in the two groups were decreased （ P ﹤ 0. 05）,moreover the decrease in the treatment group was more significant than that in the control group（ P ﹤ 0. 01）;HDL-C, ALT and serum CK after treatment in the treatment group were significantly increased compared with the control group（ P ﹤ 0. 05）;FPG and 2 h PG after treatment in the treatment group were improved compared with the control group（ P ﹤ 0. 05）. Conclusion Ro-suvastatin combined with ezetimibe can effectively improve the blood lipid level in the patients with T2DM,reduce the adverse reactions and deserve to be clinically promoted.

关 键 词：瑞舒伐他汀 依折麦布 2型糖尿病 高胆固醇 不良反应 

分 类 号：R969.4[医药卫生—药理学] R972.6[医药卫生—药学]